Compare MTA & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTA | ASMB |
|---|---|---|
| Founded | 1983 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 636.3M | 512.1M |
| IPO Year | 2017 | 2010 |
| Metric | MTA | ASMB |
|---|---|---|
| Price | $9.08 | $27.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $9.00 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 405.9K | 130.1K |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $81.63 | N/A |
| Revenue Next Year | $62.44 | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.09 | $20.23 |
| 52 Week High | $9.30 | $39.71 |
| Indicator | MTA | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 70.69 | 55.77 |
| Support Level | $6.33 | $26.29 |
| Resistance Level | $9.25 | $30.36 |
| Average True Range (ATR) | 0.33 | 1.03 |
| MACD | 0.17 | 0.16 |
| Stochastic Oscillator | 89.24 | 90.81 |
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company that engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests. Geographically, the company generates revenue from Australia, Brazil, Mexico, and the USA, with the majority generated from Brazil.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.